The discrepancy might appear from the use of distinct cell types and the use of a pharmacologic ALK inhibitor, alternatively of Cannabinoid Receptor. Twist1 has been claimed to market cell proliferation in prostate most cancers and glioma most cancers cells as described in prior publications.
